Tags : EGFR Exon 20 Insertion Mutations


Takeda’s Mobocertinib (TAK-788) Receives the US FDA’s Breakthrough Therapy Designation

Shots: Shots: The BT designation is based on P-I/II study assessing the safety and efficacy of mobocertinib (160mg, qd) in patients with LA/ m NSCLC, harboring EGFR exon 20 insertion mutations, prior treated with systemic CT The P-I/II ongoing study results: mPFS (7.3mos.); ORR (43%); safety profile was manageable. The mobocertinib development program began in […]Read More